|
Cerebrovascular accident
|
0.300 |
Biomarker
|
group |
CTD_human |
Decreased platelet glycoprotein Ib, IIb, IIIa, and IIb/IIIa and vitronectin receptor expression were observed in the stroke patient.
|
9445356 |
1998 |
|
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
|
9445356 |
1998 |
|
Cerebral Hemorrhage
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
|
9445356 |
1998 |
|
Hypertensive disease
|
0.200 |
Biomarker
|
group |
RGD |
alphaV integrins are necessary for eutrophic inward remodeling of small arteries in hypertension.
|
16380536 |
2006 |
|
Ischemia
|
0.200 |
Biomarker
|
phenotype |
RGD |
Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression.
|
15956135 |
2005 |
|
Choroidal Neovascularization
|
0.200 |
Biomarker
|
phenotype |
RGD |
Integrin alpha(v)beta3 is predominantly expressed on endothelial cells in choroidal neovascularization (CNV).
|
15287373 |
2004 |
|
Coronary Stenosis
|
0.200 |
Biomarker
|
disease |
RGD |
Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation.
|
11922905 |
2002 |
|
Corneal Neovascularization
|
0.200 |
Biomarker
|
disease |
RGD |
Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat.
|
10664059 |
2000 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Integrin subunit alpha V (ITGAV), a member of integrin family of extracellular matrix receptors, is involved in many types of cancer.
|
31320250 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCND1, GSK3B, and ITGAV of pathways in cancer were inverse correlations with miR-7-2-3p in both post-transcription and protein levels.
|
31538956 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We first show the connection between the CD51/TGF-β1/smad2/3 axis and PDAC cancer stem cell properties and then indicate that CD51-targeted therapy is a new therapeutic modality for PDAC.
|
31199988 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusions</b>: Our findings suggested that lncRNA AY promoted HCC metastasis via induction of chromatin modification for <i>ITGAV</i> transcription as a pioneer factor and was a potential molecular signature for metastasis or poor prognosis in patients with HCC.
|
31285770 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
<b>Methods:</b> Western blot and real-time PCR were used to detect the expression of ITGAV in non-tumorous tissues, osteosarcoma tissues, and metastatic tumors.
|
31239718 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues.
|
31319863 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Integrin subunit alpha V (ITGAV) is important for the diagnosis, treatment, and prognosis of tumors.
|
31239718 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT.
|
31319863 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Interestingly, the downregulation of ITGAV resulted in suppression of proliferation, migration, and invasion in GC cells.
|
31320250 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CCND1, GSK3B, and ITGAV of pathways in cancer were inverse correlations with miR-7-2-3p in both post-transcription and protein levels.
|
31538956 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Integrin subunit alpha V (ITGAV), a member of integrin family of extracellular matrix receptors, is involved in many types of cancer.
|
31320250 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We first show the connection between the CD51/TGF-β1/smad2/3 axis and PDAC cancer stem cell properties and then indicate that CD51-targeted therapy is a new therapeutic modality for PDAC.
|
31199988 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, we find that CD51 is a functional molecule that is able to promote the malignancy of PCa through enhancing tumor initiation, metastatic potential, and chemoresistance.
|
29743605 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, IL-32γ expression with NF-κB inhibitor treatment further reduced skin inflammation, epidermal hyperplasia, and cancer cell sphere formation and downregulated expression levels of ITGAV and TIMP-1.
|
30486830 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Distorted leukocyte migration, angiogenesis, wound repair and metastasis in Tspan8 and Tspan8/CD151 double knockout mice indicate complementary activities of Tspan8 and CD51.
|
29138006 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Mechanistically, we demonstrate that p53 acts via Sp1/3 to repress CD51 transcription, and CD51 is required for PCa stemness and metastasis properties, and is downregulated by p53.
|
29743605 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis.
|
29380900 |
2018 |